The DOI matches its Crossref record; 124 of the 127 references it cites were found in a registry or an index.
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
Open accessAbstract
Used since ancient times especially for the local treatment of pulmonary diseases, lungs and airways are a versatile target route for the administration of both local and systemic drugs. Despite the existence of different platforms and devices for the pulmonary administration of drugs, only a few formulations are marketed, partly due to physiological and technological limitations. Respiratory infections represent a significant burden to health systems worldwide mainly due to intrahospital infections that more easily affect immune-compromised patients. Moreover, tuberculosis (TB) is an endemic infectious disease in many developing nations and it has resurged in the developed world associated with the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic. Currently, medicine faces the specter of antibiotic resistance. Besides the development of new anti-infectious drugs, the development of innovative and more efficient delivery systems for drugs that went off patent appears as a promising strategy pursued by the pharmaceutical industry to improve the therapeutic outcomes and to prolong the utilities of their intellectual property portfolio. In this context, nanotechnology-based drug delivery systems (nano-DDS) emerged as a promising approach to circumvent the limitations of conventional formulations and to treat drug resistance, opening the hypothesis for new developments in this area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, the nanodrug delivery system reduces the adverse systemic side effects and frequency of drug administration, which eventually leads to better patient compliance.196,197”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [197]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles
Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7339 · Cited by 7,891
Cyclodextrin-based pharmaceutics: past, present and future
Davis, M. E., & Brewster, M. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1576 · Cited by 2,057
International Conference on Harmonisation
Guy, R. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,487
Labiris, N., & Dolovich, M. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01892.x · Cited by 1,212
Global Tuberculosis Control 2011, WHO Report 2011
Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,022
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 1,009
Development of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-W. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 904
Formulation strategy and use of excipients in pulmonary drug delivery
Pilcer, G., & Amighi, K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.017 · Cited by 816
Amphotericin B: side effects and toxicity
Laniado-Laborín, R., & Cabrales-Vargas, M. N. (2009) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2009.06.003 · Cited by 739
Influence of particle size on regional lung deposition – What evidence is there?
Carvalho, T. C., Peters, J. I., & Williams III, R. O. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.040 · Cited by 614
Cited by
Sorted by citations
Items 201–246 of 246
Devrim, B., & Alemdar, M. (2015) · Turkish Journal of Pharmaceutical Sciences · doi:10.5505/tjps.2016.46330 · Cited by 2
Lima, F. R. A., Campos, L. C., Macedo, G. C., Avila, H. D., & Sant’Ana, A. C. (2021) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2021.119660 · Cited by 2
Nanocarriers: A boon to the drug delivery systems
Upadhyay, L. S. B., & Kumar, N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88450-1.00019-3 · Cited by 2
Nano-targeted drug delivery approaches for viral infections
Gebrecherkos, T., Dejene, T. A., Barabadi, H., Mostafavi, E., & Saravanan, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90792-7.00015-4 · Cited by 2
Drug Delivery Systems for Respiratory Infections
Padhi, S., & Behera, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-4392-7_22 · Cited by 2
Nanoengineering Approaches to Fight Multidrug-Resistant Bacteria
Seena, S., & Rai, A. (2023) · Springer eBooks · doi:10.1007/978-981-19-9167-7_9 · Cited by 2
Current State of the Potential Use of Chitosan as Pharmaceutical Excipient
Madureira, A. R., Sarmento, B. F. C. C., & Pintado, M. (2015) · Wiley eBooks · doi:10.1002/9781119041450.ch9 · Cited by 2
Self-citationRevisiting the nano option for overcoming antibiotic resistance
Schwendeman, S. P. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.026 · Cited by 2
The Current Status and Prospects of Poly(Lactic Acid) Applications in Clinical Treatment
Yang, Z., Qiao, C., Liu, J., Qin, T., Gao, P., Chen, J., & Yin, G. (2024) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2024.3826 · Cited by 1
Caijiao, X., Zhou, S., Yunfan, B., Xu, H., Ruishi, X., Xu, L., Zhu, M., Luo, H., Wei, K., & Fang, X. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126901 · Cited by 1
Tan, J., Tian, J., Hou, H., Alarfaj, A. A., Arulselvan, P., & Fan, D. (2026) · 3 Biotech · doi:10.1007/s13205-026-05053-x · Cited by 1
Nano Science in Pulmonary Drug Delivery
Prajapati, B. G., & Varia, U. (2021) · doi:10.47363/jnsrr/2021(3)122 · Cited by 1
Bioinspired green synthesis of nanoparticles by plants to fight against multidrug resistant microbes
SHENDE, S. S., Ingle, P. U., Sonawane, A., Jungari, P., Rajput, V. D., Minkina, T., Prokisch, J., Golińska, P., Rai, M., & Gade, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29044-2.00019-9 · Cited by 1
Nanoparticle Formulations and Delivery Strategies for Sustained Drug Release in the Lungs
Cuestas, M. L., Devoto, T. B., Toscanini, M. A., Limeres, M. J., Islan, G. A., & Castro, G. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821185-4.00002-6 · Cited by 1
Mechanistic Insights of Actions of Metal Nanoparticles on Multidrug-Resistant Bacteria
Alzahrani, S. S. S., Ali, H. M., & Ahmed, M. M. M. (2021) · OnLine Journal of Biological Sciences · doi:10.3844/ojbsci.2021.346.353 · Cited by 1
Alginate-Based Drug Delivery Systems for Respiratory Disease
Gupta, R., Dan, D., Singh, A., & Nimisha (2023) · Springer eBooks · doi:10.1007/978-981-19-7656-8_19 · Cited by 1
Liposomes for Delivery of Antitubercular Drugs
Shrivastava, P., Gautam, L., Vyas, S., & Vyas, S. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-14100-3_8 · Cited by 1
Nanostrategies for Infectious Pulmonary Diseases: Current Progress and Future Prospects
Nadaf, D. S., Kumbhar, P., Bhagwat, D. A., & Gurav, S. S. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781837672813-00025 · Cited by 1
Shiohama, Y., Nakamura, J., & Nakamura, M. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c02051 · Cited by 1
Recent advances in nanomedicines for the treatment of global infectious diseases
Jatinder, K., Anjali, Kaur, J., Rani, P., Mundlia, P., Singh, S., Shukla, R., Suttee, A., Barnwal, R. P., & Singh, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13337-4.00010-0 · Cited by 1
Aerosol Therapy Development and Methods of Increasing Nebulization Effectiveness
Matuszak, M., Ochowiak, M., & Doligalski, M. (2018) · Lecture notes on multidisciplinary industrial engineering · doi:10.1007/978-3-319-73978-6_19 · Cited by 1
Light-Activated Nanoparticles for Antibacterial Studies
Varier, K. M., Liu, W., Ben‐David, Y., Li, Y., Chinnasamy, A., & Gajendran, B. (2019) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-030-16427-0_8 · Cited by 1
Nanotechnology: A Twenty-First-Century Approach Towards the Control of Antibiotic-Resistant Bacteria
Sagar, S. S., Kaistha, S. D., Das, A. J., & Kumar, R. (2019) · Springer eBooks · doi:10.1007/978-981-13-9879-7_10 · Cited by 1
Is Micro and Nanotechnology Helping Us Fight Histoplasmosis?
de Sousa, F. M. B. T., Ferreira, D., Reis, S., & Costa, P. C. (2023) · Infectious diseases · doi:10.5772/intechopen.110544 · Cited by 1
Self-citationImprovement of anti-inflammation of swietenia macrophylla self nanoemulsion
Eid, A. M., & Mustafa, A. (2015)
de Assis, L. C., de Castro, A. A., Ramalho, T. C., Taft, C. A., & Porta, F. A. L. (2021) · Engineering materials · doi:10.1007/978-3-030-62226-8_19
Talaei, S., Mellatyar, H., Mohammadi, S., Panahi, Y., Kianpour, P., Akbarzadeh, A., & Zarghami, N. (2020) · EURAS Journal of Health · doi:10.17932/ejoh.2020.022/ejoh_v02i1001
Nanovesicles for the delivery of antibiotics
Ain, Q. U., Hussain, N., Attique, S. A., & Bilal, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91865-7.00005-5
Sabuj, M. Z. R. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.239284
Tissue-based in vitro and ex vivo models for pulmonary permeability studies
Rafael, D. F. D. S., & Andrade, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15510-9.00026-8
Self-citationThe design for drug delivery using pili in Mycobacterium tuberculosis
Ghanavi, J., Farnia, P., Aghajani, J., Ayoubi, S., Besharati, S., Farnia, P., & Velayati, A. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21712-8.00020-x
Dinanti, F. P., Erawati, T., & Hariyadi, D. M. (2025) · Tropical Journal of Natural Product Research · doi:10.26538/tjnpr/v9i6.7
Emerging Therapeutic Treatments for Multidrug-Resistant Bacteria: A Review
Wang, Y. (2025) · International Journal of Biology and Life Sciences · doi:10.54097/p98n9f69
Biomimetic Nanoparticles in Pulmonary Medicine: Innovations and Future Prospects
Khawas, S., Anand, K., Singh, A., & Sharma, N. (2025) · Biomedical Materials & Devices · doi:10.1007/s44174-025-00617-6
Formulating for the lungs: recent trends in liquid, dry, and hybrid inhalation technologies
Ren, G. (2025) · Journal of clinical technology and theory. · doi:10.54254/3049-5458/2025.30514
Development and characterization of a carrier-free dry powder inhaler formulation of clarithromycin
Aygüler, C. İ., Fael, H., Hacıoğlu, M., & Yıldız-Peköz, A. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107495
Smart Nanocarriers and AI-Driven Release Systems for Targeted Antibiotic Delivery
Kostas, R. Y., Bozbeyoğlu, P., Altuner, E. E., & Elmas, M. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-5268-8.ch007
AI-Driven Innovations in Pulmonary Medicine
Aminabee, S. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-7759-9.ch011
Perucchini, M., Vigani, B., Valentino, C., Ruggeri, M., Sandri, G., & Rossi, S. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s599438
Solid Lipid Nanoparticles Based Dry Powder Inhalers for Enhanced Drug Delivery Against Lung Diseases
Onel, C., Tok, Y. P., & Özsoy, Y. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03513-4
Inhaled lipid nanoparticle–RNA delivery systems: Challenges and breakthroughs
Shi, Y., Huang, S., Wen, Z., Meng, Y., Yu, J., Du, S., Liu, Y., & Xia, X. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.09.032
Metadata
- Authors
- Andrade, F., Rafael, D., Videira, M., Ferreira, D., Sosnik, A., & Sarmento, B.
- Affiliations
- Universidade do Porto (PT)
- University of Lisbon (PT)
- Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
- Corresponding author
- Andrade, Fernanda
- Sarmento, Bruno
- ORCID
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 65
- Issue
- 13-14
- Pages
- 1816-1827
- ISSN
- 0169-409X (ISSN-L)
- PMC
- PMC7103277
- OpenAlex
- W2010047058
- Cited by
- 245
- References
- 127
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 23 · 2023: 22 · 2022: 21 · 2021: 29 · 2020: 23 · 2019: 26 · 2018: 11 · 2017: 17 · 2016: 10 · 2015: 19 · 2014: 16 · 2013: 1
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Advanced Drug Delivery Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundação para a Ciência e a Tecnologia (FCT) (SFRH/BD/73062/2010)
- FCT (Portugal)/Ministry of Science, Technology and Innovation (MINCyT, Argentina)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- pulmonary drug delivery, respiratory infections, tuberculosis, HIV/AIDS, antibiotic resistance, immunocompromised patients
- MeSH terms
- Administration, Inhalation, Animals, Anti-Infective Agents, Chemistry, Pharmaceutical, Drug Carriers, Drug Resistance, Microbial, Equipment Design, Humans, Nebulizers and Vaporizers, Respiratory Tract Infections, Nanotechnology, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
